No evidence suggests that Pfizer’s smoking cessation medication Chantix increases the risk of cancer; recall of this product is irrelevant to the safety of COVID-19 vaccines
The recall of Chantix, a smoking cessation aid developed by Pfizer, wasn’t related to the actual ingredients in the product. The company took this precautionary measure after finding nitrosamine impurities that exceeded the recommended limits in certain batches of the drug. Although some nitrosamines compounds may increase cancer risk in humans, there is no evidence that the particular one found in Chantix poses a health risk.